We then treated mice bearing disseminated prostate cancer lesions at 2 different stages of disease with 177Lu- and 225Ac-PSMA-617 as single agents, or in combination, to compare therapeutic efficacy and survival. This evidence concerns the gene FOLH1 and Familial prostate cancer.